> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Clarametyx Gets Fast Track for Pulmonary Infection Drug
- URL: https://www.fdaweb.com/clarametyx-gets-fast-track-for-pulmonary-infection-drug/
- Published: 2025-08-05T12:00:00.000Z
- Updated: 2026-09-14T15:18:20.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5159625

FDA has granted Clarametyx Biosciences both fast track and qualified infectious disease product designations for its lead therapeutic candidate, CMTX-101, and its use in treating chronic bacterial pulmonary infections in people with cystic fibrosis (CF).

The designations follow “encouraging interim results” from Clarametyx’s ongoing Phase 1b/2a clinical trial of CMTX-101 in CF patients, according to the company. The trial, which builds on standard-of-care therapy, is evaluating safety, pharmacokinetics, immunogenicity, and the therapy’s effect on pulmonary burden of *Pseudomonas aeruginosa*, it says, adding that an interim analysis of the first 21 participants met pre-specified criteria, allowing the study to expand to additional patients and clinical sites.

Clarametyx describes CMTX-101 as an investigational antibody therapy designed to dismantle bacterial biofilms — a key structural component that protects bacteria and contributes to chronic infection and inflammation. By targeting this pro-inflammatory biofilm structure, the therapy aims to boost antibiotics’ and the immune system’s effectiveness, offering potential treatment across a range of bacterial infections. In addition to CF, Clarametyx sees future opportunities for CMTX-101 in conditions such as non-CF bronchiectasis, nontuberculous mycobacterial lung disease, and chronic obstructive pulmonary disease.